Johnson Wendy S. 4
4 · Reneo Pharmaceuticals, Inc. · Filed Jul 15, 2021
Insider Transaction Report
Form 4
Johnson Wendy S.
Chief Development Officer
Transactions
- Sale
Common Stock
2021-07-14$8.50/sh−111,736$949,756→ 0 total
Footnotes (1)
- [F1]The Reporting Person previously notified the Issuer of her intention to retire from her position as the Issuer's Chief Development Officer, effective on or before December 31, 2021. Following her announcement, the Reporting Person exercised an option totaling 111,736 shares of Common Stock of the Issuer (the "Shares") on July 8, 2021. The Reporting Person is selling the Shares privately to Abingworth Bioventures 8 LP ("Abingworth"), an existing stockholder of the Issuer. Bali Muralidhar, a Director of the Issuer, is a member of the investment committee of Abingworth.